Open Label Study of TRx0014 in Alzheimer's Disease

Inclusion Criteria

• •The patient may be of either sex and must be supervised by a carer who is competent to ensure compliance with the medication and who is willing to participate in completing the various assessments. The carer must provide written consent to his or her own participation in the study.
• •Patients with capacity must give written informed consent to participate in this study. Patients who lack capacity to consent must be in agreement with entering into the study and have a personal legal representative giving written informed consent to their participation.
• •The patient must have been ongoing in TRx-014-001 at time of study termination.